SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Wick A) "

Search: WFRF:(Wick A)

  • Result 1-10 of 78
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Aaltonen, T., et al. (author)
  • Combination of CDF and D0 measurements of the W boson helicity in top quark decays
  • 2012
  • In: Physical Review D. - 1550-7998 .- 1550-2368. ; 85:7, s. 071106-
  • Journal article (peer-reviewed)abstract
    • We report the combination of recent measurements of the helicity of the W boson from top quark decay by the CDF and D0 collaborations, based on data samples corresponding to integrated luminosities of 2.7-5.4 fb(-1) of p (p) over bar collisions collected during Run II of the Fermilab Tevatron collider. Combining measurements that simultaneously determine the fractions of W bosons with longitudinal (f(0)) and right-handed (f(+)) helicities, we find f(0) = 0.722 +/- 0.081[+/- 0.062(stat) +/- 0.052(syst)] and f(+) = -0.033 +/- 0.046[+/- 0.034(stat) +/- 0.031(syst)]. Combining measurements where one of the helicity fractions is fixed to the value expected in the standard model, we find f(0) = 0.682 +/- 0.057[+/- 0.035(stat) +/- 0.046(syst)] for fixed f(+) and f(+) = -0.015 +/- 0.035[+/- 0.018(stat) +/- 0.030(syst)] for fixed f(0). The results are consistent with standard model expectations.
  •  
2.
  • Aaltonen, T., et al. (author)
  • Evidence for a Particle Produced in Association with Weak Bosons and Decaying to a Bottom-Antibottom Quark Pair in Higgs Boson Searches at the Tevatron
  • 2012
  • In: Physical Review Letters. - 0031-9007 .- 1079-7114. ; 109:7, s. 071804-
  • Journal article (peer-reviewed)abstract
    • We combine searches by the CDF and D0 Collaborations for the associated production of a Higgs boson with a W or Z boson and subsequent decay of the Higgs boson to a bottom-antibottom quark pair. The data, originating from Fermilab Tevatron p (p) over bar collisions at root s = 1.96 TeV, correspond to integrated luminosities of up to 9.7 fb(-1). The searches are conducted for a Higgs boson with mass in the range 100-150 GeV/c(2). We observe an excess of events in the data compared with the background predictions, which is most significant in the mass range between 120 and 135 GeV/c(2). The largest local significance is 3.3 standard deviations, corresponding to a global significance of 3.1 standard deviations. We interpret this as evidence for the presence of a new particle consistent with the standard model Higgs boson, which is produced in association with a weak vector boson and decays to a bottom-antibottom quark pair.
  •  
3.
  • Bousquet, J., et al. (author)
  • ARIA 2016 : Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
  • 2016
  • In: Clinical and Translational Allergy. - : Wiley. - 2045-7022. ; 6:1
  • Research review (peer-reviewed)abstract
    • The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA - disseminated and implemented in over 70 countries globally - is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
  •  
4.
  • Helbig, K. L., et al. (author)
  • De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and Dyskinesias
  • 2018
  • In: American Journal of Human Genetics. - : Elsevier BV. - 0002-9297 .- 1537-6605. ; 103:5, s. 666-678
  • Journal article (peer-reviewed)abstract
    • Developmental and epileptic encephalopathies (DEEs) are severe neurodevelopmental disorders often beginning in infancy or early childhood that are characterized by intractable seizures, abundant epileptiform activity on EEG, and developmental impairment or regression. CACNA1E is highly expressed in the central nervous system and encodes the alpha(1)-subunit of the voltage-gated Ca(V)2.3 channel, which conducts high voltage-activated R-type calcium currents that initiate synaptic transmission. Using next-generation sequencing techniques, we identified de novo CACNA1E variants in 30 individuals with DEE, characterized by refractory infantile-onset seizures, severe hypotonia, and profound developmental impairment, often with congenital contractures, macrocephaly, hyperkinetic movement disorders, and early death. Most of the 14, partially recurring, variants cluster within the cytoplasmic ends of all four S6 segments, which form the presumed Ca(V)2.3 channel activation gate. Functional analysis of several S6 variants revealed consistent gain-of-function effects comprising facilitated voltage-dependent activation and slowed inactivation. Another variant located in the domain II S4-S5 linker results in facilitated activation and increased current density. Five participants achieved seizure freedom on the anti-epileptic drug topiramate, which blocks R-type calcium channels. We establish pathogenic variants in CACNA1E as a cause of DEEs and suggest facilitated R-type calcium currents as a disease mechanism for human epilepsy and developmental disorders.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • Andersson, Mattias K, 1979, et al. (author)
  • ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma
  • 2020
  • In: Oncogenesis. - : Springer Science and Business Media LLC. - 2157-9024. ; 9
  • Journal article (peer-reviewed)abstract
    • Adenoid cystic carcinoma (ACC) is a rare cancer that preferentially occurs in the head and neck, breast, as well as in other sites. It is an aggressive cancer with high rates of recurrence and distant metastasis. Patients with advanced disease are generally incurable due to the lack of effective systemic therapies. Activation of the master transcriptional regulator MYB is the genomic hallmark of ACC. MYB activation occurs through chromosomal translocation, copy number gain or enhancer hijacking, and is the key driving event in the pathogenesis of ACC. However, the functional consequences of alternative mechanisms of MYB activation are still uncertain. Here, we show that overexpression of MYB or MYB-NFIB fusions leads to transformation of human glandular epithelial cells in vitro and results in analogous cellular and molecular consequences. MYB and MYB-NFIB expression led to increased cell proliferation and upregulation of genes involved in cell cycle control, DNA replication, and DNA repair. Notably, we identified the DNA-damage sensor kinase ATR, as a MYB downstream therapeutic target that is overexpressed in primary ACCs and ACC patient-derived xenografts (PDXs). Treatment with the clinical ATR kinase inhibitor VX-970 induced apoptosis in MYB-positive ACC cells and growth inhibition in ACC PDXs. To our knowledge, ATR is the first example of an actionable target downstream of MYB that could be further exploited for therapeutic opportunities in ACC patients. Our findings may also have implications for other types of neoplasms with activation of the MYB oncogene.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 78
Type of publication
journal article (67)
conference paper (5)
research review (5)
book chapter (1)
Type of content
peer-reviewed (67)
other academic/artistic (11)
Author/Editor
Wick, MC (11)
Wick, Mary Jo, 1963 (11)
Wick, P (8)
Fadeel, B (7)
Chinot, Olivier (7)
Henriksson, Roger (6)
show more...
Wick, M. (6)
Stark, A (6)
Buerki-Thurnherr, T (6)
Weller, Michael (6)
Taphoorn, Martin J. ... (6)
Stupp, Roger (6)
Reijneveld, Jaap C (6)
Dirven, Linda (6)
Prato, M. (5)
Bianco, A. (5)
Hoang-Xuan, Khe (5)
Aaronson, Neil K. (4)
Vencovsky, J (4)
Lundberg, IE (4)
Saran, Frank (4)
Wick, C (4)
Vazquez, E (4)
Pelin, M (4)
Mason, Warren (4)
Nishikawa, Ryo (4)
Carpentier, Antoine ... (4)
Kavan, Petr (4)
Gauthier, L. (3)
Price, D. (3)
Ljungqvist, Olle, 19 ... (3)
Lobo, Dileep N (3)
Heinrich, J. (3)
Tubaro, A (3)
Falås, Per (3)
Weiss, RJ (3)
Dastmalchi, M (3)
Mohseni, Shahin, 197 ... (3)
Magnusson, Maria K, ... (3)
Palmblad, K (3)
Weiss, R. J. (3)
Krystufkova, O (3)
Wenzel, Ulf Alexande ... (3)
Baker, J (3)
Malmström, Annika (3)
Ballerini, L. (3)
Wu, Christopher L (3)
Urman, Richard D. (3)
Wick, W. (3)
Hubner, Martin (3)
show less...
University
Karolinska Institutet (40)
University of Gothenburg (14)
Umeå University (9)
Linköping University (9)
Lund University (7)
Uppsala University (6)
show more...
Örebro University (6)
Linnaeus University (2)
Royal Institute of Technology (1)
Stockholm University (1)
University of Skövde (1)
Swedish University of Agricultural Sciences (1)
show less...
Language
English (78)
Research subject (UKÄ/SCB)
Medical and Health Sciences (33)
Natural sciences (6)
Engineering and Technology (2)
Social Sciences (2)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view